Key Points
- Director Mark Pacala sold 50,000 shares on Nov. 18 at an average price of $4.00 for $200,000, reducing his stake by 22.23% to 174,971 shares (valued at roughly $699,884).
- The company reported quarterly EPS of ($0.14) (missing the ($0.12) estimate) while revenue beat at $136.56 million; shares traded at $3.10 and the stock has a 52-week range of $0.14–$4.88 with a market cap near $289.4 million.
- Analysts hold a consensus rating of "Moderate Buy" with a $7.00 consensus price target, reflecting mixed analyst views (one Strong Buy, two Buy, one Sell).
-logo-1200x675.png?v=20220303080937)
The Oncology Institute, Inc. (NASDAQ:TOI - Get Free Report) Director Mark Pacala sold 50,000 shares of the company's stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $4.00, for a total transaction of $200,000.00. Following the completion of the sale, the director directly owned 174,971 shares of the company's stock, valued at $699,884. The trade was a 22.23% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.
Oncology Institute Stock Performance
Shares of Oncology Institute stock traded down $0.15 on Friday, reaching $3.10. 378,261 shares of the company traded hands, compared to its average volume of 1,666,279. The company has a 50 day moving average of $3.78 and a 200 day moving average of $3.35. The company has a debt-to-equity ratio of 14.58, a current ratio of 1.68 and a quick ratio of 1.39. The Oncology Institute, Inc. has a 52 week low of $0.14 and a 52 week high of $4.88. The firm has a market capitalization of $289.38 million, a PE ratio of -4.84 and a beta of 0.07.
Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.02). The firm had revenue of $136.56 million during the quarter, compared to the consensus estimate of $122.63 million. Oncology Institute had a negative net margin of 13.21% and a negative return on equity of 1,527.21%. Oncology Institute has set its FY 2025 guidance at EPS.
Institutional Inflows and Outflows
A number of hedge funds have recently added to or reduced their stakes in TOI. ProShare Advisors LLC purchased a new stake in Oncology Institute in the second quarter worth about $25,000. Police & Firemen s Retirement System of New Jersey purchased a new stake in shares of Oncology Institute in the 2nd quarter worth about $32,000. Cetera Investment Advisers increased its stake in shares of Oncology Institute by 35.0% in the 2nd quarter. Cetera Investment Advisers now owns 17,545 shares of the company's stock worth $36,000 after acquiring an additional 4,545 shares in the last quarter. State of Wyoming purchased a new position in Oncology Institute during the 2nd quarter valued at about $37,000. Finally, Prelude Capital Management LLC bought a new stake in Oncology Institute during the third quarter worth about $41,000. 36.86% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
TOI has been the topic of a number of recent analyst reports. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oncology Institute in a research note on Wednesday, October 8th. BTIG Research reaffirmed a "buy" rating and set a $7.00 price objective on shares of Oncology Institute in a report on Tuesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $7.00.
Read Our Latest Analysis on Oncology Institute
Oncology Institute Company Profile
(
Get Free Report)
The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
